Diligence memo · auto-generated · as of July 2, 2026
Hallux, Inc.
Hallux, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Hallux, Inc. operates in Pharmaceuticals, based in LAGUNA HILLS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Hallux, Inc. has raised $20M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2022-03-31.
Most recent recorded round closed around 2022-03-31.
Valuation (modeled)modeled
Provath models Hallux, Inc. at approximately $152M (range $12M–$551M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 4.65× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 66% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc., Groff North America, LLC.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.